News

The two-year grant will be utilized for RegeneRx’ phase II clinical trial, which is currently enrolling patients. Epidermolysis bullosa (EB) is a rare, often devastating, genetic disease that

Current FDA guidelines for both pediatric and adult patients recommend at least weekly face-to-face visits with a health practitioner during the first four weeks of antidepressant treatment, then

The cheese is part of the Reducol-based range produced by biopharmaceutical company Forbes Medi-Tech. It will be available at Tesco stores by the end of August, 2006. Reducol

AN2690 is the first in a new class of antifungal agents that is being developed for onychomycosis, a fungal infection of the nail and nail bed. The 15

HepaVaxx B Vaccine consists of a recombinant chimeric molecule containing a hepatitis B viral antigen and a portion of a murine monoclonal antibody. The molecule is designed to

Elara is a spinout company dedicated to drug development and will follow up on promising small molecule leads that have shown powerful anticancer actions in screening experiments. Elara

Under the agreement, GlaxoSmithKline has paid Genstruct an upfront fee pursuant to an agreement signed in 2005 and will continue to fund research projects for the term of

Working closely with the New Zealand Ministry of Health and drawing upon earlier work at the Norwegian Institute of Public Health, Novartis scientists developed and manufactured the MeNZB

Five patients, three men and two women ranging in age from 22 to 54, with a genetic form of precancerous lesions in the bowel (familial adenomatous polyposis, or